- Regulation of pituitary adenylyl cyclase-activating polypeptide (PACAP, ADCYAP1: adenylyl cyclase-activating polypeptide 1) in the treatment of schizophrenia
[作者:Matsttzaki, S; Tohyama, M,期刊:Expert Opinion on Therapeutic Targets, 页码:1097-1108 , 文章类型: Review,,卷期:2008年12-9]
- Background: Deficiency of pituitary adenylyl cyclase-activating polypeptide (PACAP) and its specific receptor, PAC1, causes a schizophrenia-like phenotype in mice. In addition, the relation of the PACAP and PAC1 genes to...
- Akt as a therapeutic target in cancer
[作者:Steelman, LS; Stadelman, KM; Chappell, WH; Horn, S; Basecke, J; Cervello, M; Nicoletti, F; Libra, M; Stivala, F; Martelli, AM; McCubrey, JA,期刊:Expert Opinion on Therapeutic Targets, 页码:1139-1165 , 文章类型: Review,,卷期:2008年12-9]
- Background: The phosphatidylinositol 3-kinase (PI3K)/phosphatase and tensin homolog (PTEN)/v-akt murine thymoma viral oncogene homolog (Akt)/mammalian target of rapamycin (mTOR) pathway is central in the transmission of ...
|